European Respiratory Society International Congress 2024,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

European Respiratory Society International Congress 2024
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-03 , DOI: 10.1016/s2213-2600(24)00322-9
Priya Venkatesan

Section snippets

Long-term oxygen therapy for severe hypoxaemia

To prolong survival in patients with severe resting hypoxaemia, long-term oxygen therapy is an established treatment. The recommendation for oxygen use is for at least 15 h per day. Use for 24 h per day has been suggested to prolong survival according to a non-randomised comparison, however, the 24-h regimen can be burdensome, restrict mobility, and increase the risk of adverse effects. Session chair James D Chalmers (University of Dundee, Dundee, UK) commented “The rationale for 24 h a day

Tirzepatide for obstructive sleep apnoea and obesity

Obstructive sleep apnoea and obesity are closely related conditions; additionally, excess body fat is a major risk factor for the development of obstructive sleep apnoea and associated complications including cardiovascular disease and hypertension. In previous studies, tirzepatide, a long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, was shown to reduce excess bodyweight and markers of inflammation and vascular endothelial

Sulthiame for obstructive sleep apnoea

The carbonic anhydrase inhibitor sulthiame, used in the treatment of epilepsy, has also been shown in a previous phase 2b trial to effectively reduce the number of apnoeas. Jan Hedner (University of Gothenburg, Gothenburg, Sweden) and co-researchers further investigated the efficacy of sulthiame in obstructive sleep apnoea in a randomised, dose-ranging study of 298 individuals in 28 European centres with moderate-to-severe obstructive sleep apnoea who could not use standard therapy of

Tozorakimab in COPD

Expression of the cytokine IL-33 is upregulated in the lungs of patients with COPD, which correlates with disease progression and exacerbations. In a phase 2, randomised study in 90 sites in Australia, Canada, Europe, Israel, New Zealand, South Africa, Taiwan, and the USA, Dave Singh (University of Manchester, Manchester, UK) and co-researchers investigated tozorakimab, an anti-IL-33 monoclonal antibody, in 135 patients with moderate-to-severe COPD and chronic bronchitis receiving dual-inhaled

Depemokimab in severe asthma

Several biologic therapies targeting IL-5, a key driver of uncontrolled type 2 eosinophilic inflammation in patients with severe and frequent asthma exacerbations, have been shown to improve outcomes in patients with an eosinophilic phenotype. These include biologics such as mepolizumab, which is given as a subcutaneous injection every 4 weeks, a regimen that might not be acceptable for some patients. David J Jackson (Guy's and St Thomas’ NHS Foundation Trust, London, UK) and co-workers

更新日期：2024-10-03

点击分享查看原文

点击收藏

阅读更多本刊新发论文